Twice-yearly HIV prevention drug approved in the U.S., moving PrEP into a new phase of long-acting dosing

For many people who need HIV pre-exposure prophylaxis (PrEP), whether a drug is effective is not the only issue; whether it can be used long term, regularly, and with a low burden often also determines whether protection can be realized. The U.S. Food and Drug Administration (FDA) approved Gilead Sciences’ Yeztugo (lenacapavir) for HIV prevention, adding a long-acting option given once every six months to PrEP, beyond daily oral pills and more frequent injections.

This approval applies to adults and adolescents at risk of acquiring HIV through sexual exposure and weighing at least 35 kilograms. According to FDA approval documents and Gilead’s statement, Yeztugo is injected every six months after initiation and is the first HIV prevention drug approved in the United States for twice-yearly use. WHO also noted that the approval marks a move in HIV prevention toward long-acting injectable options; subsequent CDC recommendations include it in discussions of PrEP options, while still emphasizing the importance of testing and follow-up.

The clinical evidence mainly comes from the randomized, double-blind PURPOSE 1 and PURPOSE 2 trials. Data released by Gilead state that the vast majority of participants in the two studies remained HIV-negative under the protection of long-acting lenacapavir; FDA approval documents say the trials compared Yeztugo with background HIV incidence and daily oral Truvada, covering different participant groups including cisgender women, cisgender men, transgender women, transgender men, and gender-diverse populations. These results support approval, but public summaries still cannot replace a close reading of the complete clinical data on population differences, long-term safety, and real-world use scenarios.

The public health significance of long-acting PrEP is that it may bypass some of the practical barriers to taking a daily medication. Daily medication requires a stable routine, privacy, drug access, and continued medical follow-up; for some people, these conditions are not easy to maintain at the same time. A twice-yearly injection will not eliminate barriers related to stigma, cost, or healthcare access, but it may make prevention tools better aligned with real life, especially for those who find it difficult to maintain daily pill-taking or frequent clinic visits.

The FDA also requires Yeztugo to carry a boxed warning: HIV-1 infection must be tested for before use and before each injection. The reason is that if lenacapavir is used in the setting of undiagnosed infection, drug-resistant HIV-1 variants may emerge. This requirement reminds people that long-acting drugs do not mean all medical processes are simplified; on the contrary, because the drug effect lasts a long time, correct screening and continued follow-up become central to safe use.

Commercial and access issues will also affect the real scale of this innovation. Price, insurance coverage, and public health adoption will be key areas to watch. Public reports indicate that Yeztugo’s annual cost in the United States is not low; at the same time, lenacapavir had previously been used under the Sunlenca brand for highly treatment-experienced HIV patients, while this approval is for a prevention indication. In other words, as the same molecule moves from a treatment niche into a prevention setting, it will face broader but also more sensitive issues of payment and distribution.

This approval does not mean HIV prevention now has only one answer. Oral PrEP, shorter-interval injections, insurance systems, local clinic capacity, testing frequency, and personal preferences will all jointly determine who can truly use the new drug. The most important significance of Yeztugo’s emergence may not be replacing existing tools, but adding a new time scale to HIV prevention strategies: extending from remembering one pill every day to a long-acting commitment twice a year, but one that must be precisely linked with testing and care.